Acurx Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2023

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2023 and 2022 were as follows:


	December 31, 2023		December 31, 2022
Accrued compensation expenses	$	716,307	$	542,895
Accrued research and development		2,263,934		1,405,536
Accrued professional fees		58,388		83,715
Other accounts payable and accrued expenses		3,809		29,539
Total	$	3,042,438	$	2,061,685